Dose-dense chemo before surgery for HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old
- Your breast cancer is HER2-negative, and you have a tumor bigger than 2 cm
- Your cancer is stage IIA to IIIA, and it has not spread to other organs
- You have enough strength/ability to function (ECOG 0 or 1)
- Your heart, bone marrow, liver, and kidneys all meet lab/scan thresholds
- You have not had chemotherapy, radiation, or hormone therapy before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This study tests two chemotherapy drugs, lobaplatin and carboplatin, given before surgery for HER2 positive breast cancer. The goal is to see if they are safe and help shrink the tumor before it is removed.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This Phase 2 study tests a faster, more frequent chemotherapy schedule given before surgery (neoadjuvant therapy) for certain breast cancers that grow quickly. It may help shrink the tumor before the operation and improve treatment response in people who fit the tumor and health criteria.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.